Standout Papers
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL (2009)
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010)
Immediate Impact
1 by Nobel laureates 13 from Science/Nature 94 standout
Citing Papers
Cancer Statistics, 2021
2021 Standout
Evaluating eligibility criteria of oncology trials using real-world data and AI
2021 StandoutNature
Works of J. Mezger being referenced
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010 Standout
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
2009 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| J. Mezger | 1870 | 1655 | 733 | 53 | 3.3k | |
| Petronella O. Witteveen | 1948 | 782 | 792 | 93 | 3.7k | |
| Shenhong Wu | 2882 | 1652 | 1422 | 96 | 5.3k | |
| Thomas Müller | 2490 | 2178 | 937 | 55 | 4.1k | |
| Shaodong Hong | 2807 | 1804 | 606 | 125 | 3.8k | |
| Scott I. Bearman | 1671 | 1460 | 1044 | 59 | 5.1k | |
| Andreas Schalhorn | 1785 | 795 | 608 | 89 | 2.9k | |
| Kirsten B. Goldberg | 2625 | 1239 | 949 | 66 | 4.3k | |
| Deborah Kuk | 2694 | 1806 | 605 | 78 | 4.4k | |
| Feng‐Hua Wang | 1485 | 828 | 857 | 124 | 2.8k | |
| Thomas A. Abrams | 1364 | 649 | 685 | 83 | 2.3k |
All Works
Loading papers...